stoxline Quote Chart Rank Option Currency Glossary
  
Scholar Rock Holding Corporation (SRRK)
37.67  0.72 (1.95%)    02-19 14:10
Open: 36.87
High: 38.21
Volume: 279,096
  
Pre. Close: 36.95
Low: 36.395
Market Cap: 3,526(M)
Technical analysis
2025-02-19 1:53:49 PM
Short term     
Mid term     
Targets 6-month :  49.68 1-year :  54.87
Resists First :  42.53 Second :  46.97
Pivot price 39.01
Supports First :  35.34 Second :  29.4
MAs MA(5) :  37.32 MA(20) :  40.08
MA(100) :  34.72 MA(250) :  20.77
MACD MACD :  -1.3 Signal :  -1
%K %D K(14,3) :  22.1 D(3) :  20.5
RSI RSI(14): 40.7
52-week High :  46.97 Low :  6.76
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SRRK ] has closed above bottom band by 30.9%. Bollinger Bands are 47.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 37.53 - 37.78 37.78 - 37.99
Low: 34.88 - 35.12 35.12 - 35.31
Close: 36.59 - 36.99 36.99 - 37.32
Company Description

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Headline News

Tue, 18 Feb 2025
Scholar Rock's chief commercial officer sells $171,927 in common stock - MSN

Sun, 16 Feb 2025
SRRK Stock Soars to 52-Week High, Reaching $46.38 - MSN

Fri, 14 Feb 2025
Major Equity Package: Scholar Rock Awards 371K Shares to Attract Top Industry Talent - StockTitan

Fri, 14 Feb 2025
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Thu, 13 Feb 2025
Scholar Rock (NASDAQ:SRRK) Shares Gap Down - Here's What Happened - MarketBeat

Wed, 12 Feb 2025
abrdn plc Has $6.15 Million Position in Scholar Rock Holding Co. (NASDAQ:SRRK) - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 94 (M)
Shares Float 73 (M)
Held by Insiders 1.1 (%)
Held by Institutions 117.5 (%)
Shares Short 15,600 (K)
Shares Short P.Month 15,360 (K)
Stock Financials
EPS -2.36
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.99
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -67.1 %
Return on Equity (ttm) -183.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -1.81
Sales Per Share 0
EBITDA (p.s.) -2.45
Qtrly Earnings Growth 0 %
Operating Cash Flow -189 (M)
Levered Free Cash Flow -102 (M)
Stock Valuations
PE Ratio -16.02
PEG Ratio 0
Price to Book value 38.17
Price to Sales 0
Price to Cash Flow -18.74
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android